47% institutional ownership - pretty high for this small biotech.
That would make for an unbelieveable squeeze if the study is positive in mid-August (if, in fact it releases then). Make or break.
Place your bet. Worse thing can happen is the stock get cut in half. Potential is enormous if Phase 3 data comes out a winner.